RWJ-67657 (Standard)

Overview

RWJ-67657 (Standard) is the analytical standard of RWJ-67657. This product is intended for research and analytical applications. RWJ-67657 (JNJ 3026582) is an orally active and selective p38α and p38β MAPK inhibitor with IC50s of 1 and 11 μM, respectively. RWJ-67657 displays no activity at p38γ and p38δ , and exhibits cardio protective effect. Anti-inflammatory and anti-tumor activity.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Others | Products > Research Areas > Cardiovascular Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > p38 MAPK | Products > Signaling Pathways > Reference Standards

Product Information

• Catalog No.: HY-15505R
• CAS No.: 215303-72-3
• Molecular Formula: C27H24FN3O
• Molecular Weight: 425.50
• Purity: 95%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.
• Availability: In-stock

Source

Original product source